Pretreatment Glasgow prognostic score predicts survival among patients with high PD‐L1 expression administered first‐line pembrolizumab monotherapy for non‐small cell lung cancer

BACKGROUND: There are no established biomarkers for predicting the efficacy of first‐line pembrolizumab monotherapy in patients with high programmed death‐ligand 1 (PD‐L1) expression. In this study, we investigated whether the Glasgow prognostic score (GPS), neutrophil‐to‐lymphocyte ratio (NLR), and...

Descripción completa

Detalles Bibliográficos
Autores principales: Imai, Hisao, Kishikawa, Takayuki, Minemura, Hiroyuki, Yamada, Yutaka, Ibe, Tatsuya, Yamaguchi, Ou, Mouri, Atsuto, Hamamoto, Yoichiro, Kanazawa, Kenya, Kasai, Takashi, Kaira, Kyoichi, Kaburagi, Takayuki, Minato, Koichi, Kobayashi, Kunihiko, Kagamu, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Researcher
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8525165/
https://www.ncbi.nlm.nih.gov/pubmed/34414673
http://dx.doi.org/10.1002/cam4.4220

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8525165/
https://www.ncbi.nlm.nih.gov/pubmed/34414673
http://dx.doi.org/10.1002/cam4.4220

Ejemplares similares